Page last updated: 2024-09-04

canertinib and zm 447439

canertinib has been researched along with zm 447439 in 2 studies

Compound Research Comparison

Studies
(canertinib)
Trials
(canertinib)
Recent Studies (post-2010)
(canertinib)
Studies
(zm 447439)
Trials
(zm 447439)
Recent Studies (post-2010) (zm 447439)
12496525017

Protein Interaction Comparison

ProteinTaxonomycanertinib (IC50)zm 447439 (IC50)
Aurora kinase AHomo sapiens (human)0.1315
Epidermal growth factor receptorHomo sapiens (human)0.11
Cyclin-dependent kinase 4Homo sapiens (human)0.039
G1/S-specific cyclin-D1Homo sapiens (human)0.039
Aurora kinase AMus musculus (house mouse)0.039
Aurora kinase B-AXenopus laevis (African clawed frog)0.045
Aurora kinase BHomo sapiens (human)0.1213

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (50.00)24.3611
2020's1 (50.00)2.80

Authors

AuthorsStudies
Das, D; Hong, J1
Bansal, R; Malhotra, A1

Reviews

2 review(s) available for canertinib and zm 447439

ArticleYear
Recent advancements of 4-aminoquinazoline derivatives as kinase inhibitors and their applications in medicinal chemistry.
    European journal of medicinal chemistry, 2019, May-15, Volume: 170

    Topics: Animals; Antineoplastic Agents; Chemistry Techniques, Synthetic; Humans; Neoplasms; Protein Kinase Inhibitors; Quinazolines

2019
Therapeutic progression of quinazolines as targeted chemotherapeutic agents.
    European journal of medicinal chemistry, 2021, Feb-05, Volume: 211

    Topics: Animals; Antineoplastic Agents; Cell Proliferation; Enzyme Inhibitors; Humans; Molecular Structure; Neoplasms; Quinazolines

2021